On Thursday, Expedia Inc (NASDAQ:EXPE)’s shares declined -4.09% to $121.60.
Expedia, Inc. (EXPE) declared that it has selected award-winning architecture firm Bohlin Cywinski Jackson (BCJ) to design its new 40-acre waterfront campus in Seattle. Expedia plans to relocate to the new campus in the City of Seattle from its current location in downtown Bellevue by 2018.
Expedia’s future campus is ideally situated at the north end of Seattle’s waterfront, which is in the midst of a billion dollar redevelopment and re-emergence as a world-class park, and located just minutes from downtown Seattle and along the Elliott Bay shoreline. It is also steps from the Seattle Art Museum’s 8.5-acre outdoor sculpture park and Myrtle Edwards Park.
The 50-year-old firm is highly-regarded for its elegant, innovative and responsive design, in addition to its ability to bring these attributes to a wide range of client projects and building types. The firm recently designed technology company Square’s new 100,000 sq. ft. corporate headquarters in San Francisco and is the lead design firm for several Apple retail stores, counting its stunning Fifth Avenue store in New York. Locally, BCJ designed Seattle City Hall with Bassetti Architects and the Ballard Library. The firm was also hand-selected by Steve Jobs to design Pixar’s open, collaborative corporate headquarters in 1999.
Expedia, Inc., together with its auxiliaries, operates as an online travel company in the United States and internationally. The company operates in two segments, Leisure and Egencia. It provides travel products and services to leisure and corporate travelers, offline retail travel agents, and travel service providers through a portfolio of brands, counting Expedia.com, Hotels.com, Hotwire.com, Classic Vacations, Travelocity, Expedia Local Expert, Egencia, Expedia CruiseShipCenters, eLong, and Venere.com, in addition to trivago, CarRentals.com, Wotif.com, lastminute.com.au, travel.com.au, Asia Web Direct, LateStays.com, GoDo.com.au, and Arnold Travel Technology.
Zoetis Inc (NYSE:ZTS)’s shares dropped -0.72% to $48.26.
The Board of Directors of Zoetis Inc. (ZTS) has declared a third quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share. The dividend is to be paid on Tuesday, Sept. 1, 2015, to holders of record on Thursday, Aug. 13, 2015.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms.
At the end of Thursday’s trade, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)‘s shares dipped -4.27% to $0.168.
Aeterna Zentaris Inc. (AEZS) declared that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology (collectively, the “Optionee”), an option to license the Company’s live recombinant oral allogenic tumor vaccine technology (the “Technology”), counting AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial. This option is granted to the Optionee worldwide, for a period of twelve months, in exchange for an upfront fee.
Following the option agreement, the Optionee has the right to obtain a worldwide exclusive license to develop, use and sell products regarding the Technology and AEZS-120, in exchange for milestone payments and royalties on net sales of any product developed from the Technology and an equity interest in the company formed to develop the Technology. At the present time, Aeterna Zentaris holds worldwide rights to the Technology, counting AEZS-120.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Atwood Oceanics, Inc. (NYSE:ATW), ended its Thursday’s trading session with 6.34% gain, and closed at $20.45.
Atwood Oceanics, Inc. (ATW) declared that one of its auxiliaries had reached a contract for a six-month extension of its existing contract with Eni S.p.A. for the jackup rig, the Atwood Beacon. The Atwood Beacon commenced its initial two-year drilling services contract with Eni on December 24, 2013, for operations offshore Italy. The agreement revises the day rate to €117,155, inclusive of equipment upgrade costs, from €135,100 starting March 1, 2015 and extends the Atwood Beacon`s firm commitment from December 24, 2015 through June 2016.
Atwood Oceanics, Inc. is a leading offshore drilling contractor engaged in the drilling and completion of exploratory and developmental wells for the global oil and gas industry. The Company presently owns 12 mobile offshore drilling units and is constructing two ultra-deepwater drillships. The Company was founded in 1968 and is headquartered in Houston, Texas. Atwood Oceanics, Inc. common stock is traded on the New York Stock Exchange under the symbol “ATW.”
Atwood Oceanics, Inc., an offshore drilling contractor, engages in the drilling and completion of exploratory and developmental oil and gas wells worldwide. As of November 10, 2014, it owned a fleet of 13 mobile offshore drilling units, in addition to 3 ultra-deepwater drill ships under construction. The company was founded in 1968 and is headquartered in Houston, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
